Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

BACKGROUND: Early clinical data from studies of the NVX-CoV2373 vaccine (Novavax), a recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that contains the full-length spike glycoprotein of the prototype strain plus Matrix-M adjuvant, showed that the...

Full description

Saved in:
Bibliographic Details
Published in:N Engl J Med
Main Authors: Heath, Paul T., Galiza, Eva P., Baxter, David N., Boffito, Marta, Browne, Duncan, Burns, Fiona, Chadwick, David R., Clark, Rebecca, Cosgrove, Catherine, Galloway, James, Goodman, Anna L., Heer, Amardeep, Higham, Andrew, Iyengar, Shalini, Jamal, Arham, Jeanes, Christopher, Kalra, Philip A., Kyriakidou, Christina, McAuley, Daniel F., Meyrick, Agnieszka, Minassian, Angela M., Minton, Jane, Moore, Patrick, Munsoor, Imrozia, Nicholls, Helen, Osanlou, Orod, Packham, Jonathan, Pretswell, Carol H., San Francisco Ramos, Alberto, Saralaya, Dinesh, Sheridan, Ray P., Smith, Richard, Soiza, Roy L., Swift, Pauline A., Thomson, Emma C., Turner, Jeremy, Viljoen, Marianne E., Albert, Gary, Cho, Iksung, Dubovsky, Filip, Glenn, Greg, Rivers, Joy, Robertson, Andreana, Smith, Kathy, Toback, Seth
Format: Artigo
Language:Inglês
Published: Massachusetts Medical Society 2021
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8262625/
https://ncbi.nlm.nih.gov/pubmed/34192426
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa2107659
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items